Thermo Fisher Scientific (TMO) saw a flurry of activity by various asset management firms. Synergy Asset Management, Annex Advisory Services, and Allspring Global Investments Holdings all significantly increased their stake in the company. For example, Ascent Group and Calamos Advisors both boosted their stock positions, while HM Payson & Co. and First American Bank increased their shares by notable amounts. At the same time, some entities reduced their holdings, such as Financiere des Professionnels Fonds d investissement and Mirova US LLC.
Improved guidance and positive Q3 results contributed to an upgrade from analysts and a possible 12% upside. The favorable performance has been attributed to Cardio testing and Bioprocessing efforts. Moreover, Thermo Fisher has been enhancing its Alzheimer’s Registry and Bioprocessing tools. Closely watched is the company’s earnings report due on January 29, 2026, as Thermo Fisher also agreed to purchase Clario Holdings for $8.88 billion, an action that may indicate Thermo Fisher's intention to accelerate innovation in pharma and biotech.
Thermo Fisher Scientific TMO News Analytics from Sun, 04 May 2025 07:00:00 GMT to Sat, 03 Jan 2026 20:01:40 GMT - Rating 7 - Innovation 5 - Information 7 - Rumor 2
